Penile ®brosis (PF) may be a complication of intracavernosal injection therapy (ICI). It has been well documented as a side effect of papaverine, but there have been few reports associating penile ®brosis with prostaglandin E1 (PGE1, Alprostadil). Many authors did not ®nd ®brotic changes in the penis while others reported penile ®brosis as a complication of intracavernosal PGE1 in only 0.76±2.1% of their patients. Recent studies, however, suggest that the incidence may be as high as 15%.
Introduction
Penile ®brosis (PF) refers to ®brotic changes in the subcutaneous tissues, the tunica albuginea or intracavernosal sinusoids of the penis. The ®rst popular description of penile ®brosis is generally attributed to Peyronie in 1743, although the condition was recognized as early as 1561 by Fallopius and Vasalius. 1, 2 There were apparently no reported cases of penile ®brosis as a complication of intracavernosal injection therapy (ICI) 2, 3 until in 1987 when Hu et al 2 described penile curvature and ®brosis in three patients receiving treatment with papaverine and phentolamine. Since then ®brotic complications of papaverine have become well recognized and documented and the prevalence has been reported to be as high as 57%.
4±6
Prostaglandin E1 (PGE1) then became the vasoactive agent of choice for intracavernosal injection therapy because it was found to be more ef®cacious and because the risk of priapism and penile ®brosis was reported to be much lower. 7±10 Amar et al, 9 Arielly et al 10 and Nisen 11 in fact reported that there was no ®brosis of cavernosal tissues or scar formation in their patients treated with PGE1. Porst 12 in 1989 found penile ®brosis and deviation in only 4 (2.1%) of his patients who received PGE1 injections. Other authors reported incidences ranging from 0.76±2%. 8,13±15 In the Schwartz Pharma Scienti®c Product Information on Virilan (Alprostadil), 16 the incidence of penile ®brosis and of penile deviation was each listed as 0.05%, based on pooled data from 44 studies involving 6145 patients. Yet, in the Product Information on Caverject (Alprostadil) dated 17 March 1995, 17 Upjohn Pty. Ltd. warned of a frequency rate of 4.8% of penile ®brosis. Lakin et al 18 reported an even higher rate of 9% in patients after one year of self-injection therapy with PGE1. In a prospective study, Porst 19 found penile indura-tions in 11.5% of his patients using PGE1, and Chen et al 20 reported an incidence of 15% in 68 of their patients without previous PF.
Patients and methods
Our study was undertaken to assess the frequency of ®brotic changes in the penis in patients receiving intracavernosal PGE1 for erectile dysfunction (ED). Between June 1995 and March 1996, 300 consecutive patients who returned to our Clinic for a further supply of PGE1 were each given a questionnaire and were asked to record the quality and duration of their erectile response and any adverse symptoms related to their use of PGE1 by self-injection. These patients were interviewed and a speci®c inquiry was made regarding penile curvature, deviation, deformity and any form of swelling in the penis. An examination of the external genitalia was performed and the patients were instructed on the technique of self-examination.
Statistical method
The proportion of men with hypertension and diabetes among patients with and without PF was analyzed using Chi-square test. Unpaired t-test was used to assess the signi®cance of the difference between patients with or without PF for each of the measured variables, when the data was normally distributed. In the comparison of the total amount and total injections used by patients, with or without PF, the Wilcoxon Scores (Rank Sums) Test was used. The relationships between the percentage of patients with PF and age, total amount of PGE1 and total number of injections were analyzed using linear regression analyses.
Results
Of the 300 consecutive patients in the study, 55 were excluded from analysis. Of these, 22 had concurrent or previous use of papaverine and/or phentolamine. Thirty had PF detected prior to commencement of ICI therapy and 3 had incomplete data. PF was detected in 57 of the remaining 245 patients (23.3%). Fibrotic changes were found mostly in the dorsal part of the penile shaft (51/ 57). Thirteen of these men with PF had penile curvature and 14 had experienced pain with ICI. Penile ultrasound was performed on 28 patients. No echogenically evident ®brosis was detected in 12. Fibrotic change was reported in 16 with extensive ®brosis in 2 and calci®cation in 2 patients.
There were 17 men with hypertension and 7 with diabetes among the patients with PF. In the group without PF, 39 had hypertension and 14 had diabetes mellitus (P b 0.1 and b 0.2 respectively).
These men with PF, mean age 62 y (21±79), had been self-injecting an average of 5.2 times per month (1±16) for an average period of 29.2 months (2±86). The mean dose of PGE1 used was 13 mg (2±60) and an average of 65.6 mg of PGE1 (3±360) was used per month. The mean total number of injections used was 142.4 (8±810) and the mean total dose of PGE1 1703 mg (105±11520).
These ®ndings were compared with those in patients who did not show clinical evidence of PF (Table 1) . Although the duration of treatment, the dose of PGE1 per injection, the number of injections and the amount of PGE1 used per month were not statistically signi®cantly different between the two groups, the total amount of PGE1 (P 0.0062) and the total number of injections (P 0.0032) over the whole treatment period were statistically signi®-cantly different. In addition there was a linear relationship (P 0.039) between total amount of PGE1 used and the percentage of patients with PF ( Figure 1 ). Age also appeared to be a signi®cant factor (P`0.0176) and, as in the case of total amount of PGE1 used, showed a linear relationship with the presence of PF, (P 0.047) (Figure 2 ). No signi®cant linear relationship was found between the total number of injections and the presence of PF.
Discussion
Whereas previously penile ®brosis was well recognized as a side effect of papaverine and PGE1 was thought to be rarely associated with this complication, the incidence of ®brotic changes in intracavernosal PGE1 therapy is now shown to be signi®cant.
Chen et al, 20 in their review of 92 patients for penile scarring, reported that there was no signi®-cant difference in terms of the number of injections, injection frequency, dose per injection or total dose of PGE1. Our study showed that age, total number of injections and total amount of PGE1 are signi®cantly different between the group of patients who developed PF and the group who did not.
Aboseif et al 21 found in their analysis of histological changes associated with intracavernosal injections of papaverine and PGE1 that, in contrast to papaverine, PGE1 led to very few changes without any complications or clinical evidence of ®brosis. The procedure of injection itself was found to produce mild in¯ammatory changes in the super®cial dermis, deep dermis and the corpus cavernosum. 22 Virag et al, 23 in their attempt to evaluate the albugineal wall thickness (AWT), found that intracavernosal injection resulted in an increase of 10.53±15.38% of AWT in various parts of the corpus cavernosum.
PF is probably not purely the result of trauma from repeated injections because, as observed by Chen et al, 20 PF in our patients occurred at locations where needles had not been inserted. The vast majority of our patients (51 out of 57) had PF along the dorsal aspect of the penile shaft. The fact that the total number of injections and total amount of PGE1 used over the whole treatment period were statistically signi®cant factors appear to indicate a cumulative in¯uence of PGE1 in the development of PF.
It is possible that PF commences as a vasculitis in the subtunical tissues 24 and continues as a chronic in¯ammation leading to perivascular ®brosis, dense plaque formation and sometimes calci®cation. 25, 26 There may also be genetic predisposition to either a ®brotic tendency or an aberrant ®brotic reaction to injury or irritation.
The natural history of PF requires further elucidation. In a study reported by Linet and Ogrinc 27 involving 683 men receiving intracavernosal PGE1 over a period of 18 months for ED, 51 men (7.5%) developed PF. Fifteen of these men continued in the study despite the ®brotic changes and in 9 of them (60%) the ®brosis completely resolved. Porst 28 also reported the disappearance within three years of ®brotic changes in 9 of the 18 patients (50%) who developed PF in the course of ICI therapy with PGE1. PF in impotent men is probably much more common than is generally recognized. Amin et al 29 found plaques, constriction and deformity of the penis in 55 of their 280 patients being assessed for erectile dysfunction (19.6% ). This compares with the prevalence of 0.39% of Peyronie's disease in the general population. 30 Thirty of our 300 patients (10%) had ®brotic changes in the penis prior to intracavernosal injection therapy. It is important that the penis be examined methodically and any ®brotic changes carefully documented before therapy is initiated. This may be complemented by ultrasound examination of the penis. However we have not found penile ultrasound a sensitive way of diagnosing or con®rming PF, nor an accurate way of assessing the extent and severity of ®brotic changes, as ultrasonographic evidence was positive in only 16 of our 28 patients with clinically evident PF (57%). Similarly Fedel et al 31 reported that ultrasound revealed evidence of morphological changes in only 59% of the palpable indurations. Lopez and Jarow 32 also remarked, in their study of Peyronie's Disease with duplex ultrasound, that ultrasonography was not as sensitive as palpation in identifying Peyronie's plaques.
From the medico-legal standpoint, patients must be speci®cally warned of risk of penile ®brosis. Where written informed consent form part of the protocol of an injection therapy programme, the possibility of penile ®brosis should be included in the patient information. There is no substitute for regular meticulous surveillance examination and patients need to be instructed on self-examination of their penis so that they may become aware of early ®brotic changes if and when these changes should occur. 
Editorial comment
Penile ®brosis in intracavernosal prostaglandin E1 injection therapy for erectile dysfunction Ð by K-K Chew et al
It is more than 10 years ago when Zorgniotti and Le¯eur published the ®rst time their experiences with self-injection therapy with the mixture of papaverine and phentolamine in a representative number of patients. 1 After some years of world-wide enthusiasm about this revolutionary new therapy in impotence papers on side-effects in self-injection therapy piled up with reports on priapisms and local penile alterations like nodules, indurations or curvatures. Not least by animal studies it seemed to be proven, that these local ®brotic changes were attributable to the toxic effects of papaverine 2, 3, 4 and so all the efforts aimed at a reduction of the dosage of papaverine. Nevertheless in some series the reported local ®brotic changes varied between 18% and 57% 5±7 revealing the necessity for the search for better tolerated vasoactive drugs. The use of prostaglandin E1 in the late eighties was associated with a reduction of priapisms below the 1% barrier as well as a considerably lower rate of local ®brotic changes in numerous publications. It was the merit of two comprehensive prospective multicenter clinical trials, launched by the pharmaceutical companies of Schwarz Pharma and Upjohn-Pharmacia and conducted according to the good clinical practice guidelines, to gain better insight into the side-effects on long-term follow-up with PGE1.
In the former clinical trial of Schwarz Pharma, which was conducted in eight European centers, the total rate of local ®brotic changes which occured during 3 y was 11.1% in 162 patients enrolled into the study, but half of these ®brotic alterations disappeared in the further course due to temporary discontinuation of self-injection therapy or improvement of the individual injection technique. Therefore a total of 5.6% of all enrolled patients showed local ®brotic changes after 3 y of follow-up.
In the latter European multicenter study of Upjohn-Pharmacia after 18 months of follow-up 7.5% of 683 involved patients developped local ®brotic changes. 8 Therefore in view of the abovementioned two prospective studies, as well as of the here presented retrospective study local ®brotic changes in the penile tissue have to be expected in 5±10% after intracavernous use of PGE1 for more than 2±3 years.
Although papaverine as well as the mixture of papaverine and phentolamine were considerably longer in use for self-injection therapy no single prospective GCP-Study of the long-term use of these drugs is available in the world-wide literature. And, in addition, nearly all of the reported retrospective studies are not considering long-term use of more than 2±3 y as well as the average number of the injections per patient. 9 Therefore from the scienti®c point of view, no comparisons between the different drugs are possible with reference to local ®brotic side-effects. With regard to the high local sideeffects up to more than 50%, reported in some retrospective studies after papaverine and phentolamine, it must be feared, that local ®brotic changes may be two-or threefold higher than after PGE1, if these drugs would be followed-up in prospective long-term studies.
The authors make an effort to differentiate between drug-related and technique-related ®brotic side effects although it remains unclear on which basis this decision is made. Nevertheless they came to the conclusion, that in six cases the ®brotic changes were related to faulty injection-technique and in seven cases to the drug PGE1 itself.
In the prospective multicenter trial of Schwarz Pharma Company, which was headed by myself, it was obvious, that those patients with a higher rate of unsuccessful injections, not resulting in rigid erections, were at higher risk for development of local ®brotic changes. Both with respect to the present retrospective series of the authors and the cited prospective studies it seems convincingly, that a very thorough introduction into the self-injection technique, which will be indeed a time-consuming undertaking in the single patient, as well as the use of ultrathin needles (27±30 gauge) and permanent alternation of the injection site may provide appropriate precautions for diminuation of local sideeffects. Last but not least the comment of the authors on the necessity of written informed consent has once more be emphasized in this context as nothing is more annoying than being involved in a lawsuit where the patient is claiming, that he was not informed on such possible side-effects of selfinjection therapy.
